Abstracts Archive - Page 1023 of 2425 - ACR Meeting Abstracts

Abstract Number: 274 • 2018 ACR/ARHP Annual Meeting
Socioeconomic Disparities in Disease Activity in Patients with Rheumatoid Arthritis
Lei Zhu¹, Evelyn Talbott² and Larry W. Moreland¹, ¹Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology, University of Pittsbugh, Pittsburgh, PA
Background/Purpose: To develop a methodology for well-defined rheumatoid arthritis (RA) measurement as an outcome and provide a clear definition of social determinants related to disease…
Abstract Number: 275 • 2018 ACR/ARHP Annual Meeting
Health Equity: Access to Rituximab for Patients Comparing Variable Access in a Single Rheumatology Clinic
Raymond Chu¹, Catherine Mallon¹, Jan Willem Cohen Tervaert¹ and Elaine Yacyshyn², ¹University of Alberta, Edmonton, AB, Canada, ²Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The purpose of our study is to investigate the difference in time to access of rituximab therapy between patients with rheumatoid arthritis (RA) compared…
Abstract Number: 276 • 2018 ACR/ARHP Annual Meeting
Gender Differences in TNFi Treatment Adherence and Response in As Patients: A Prospective Longitudinal Cohort Study
S. Hoekstra¹, Tamara Rusman², Michael T. Nurmohamed³, Christiaan van Denderen⁴ and Irene van der Horst-Bruinsma⁵, ¹Rheumatology, VU Univeresity Medical Center, Amsterdam, Netherlands, ²Rheumatology, VU University medical centre, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Despite several observations of gender differences in TNF inhibitor (TNFi) treatment response and adherence in ankylosing spondylitis (AS) patients, limited studies were conducted. Our…
Abstract Number: 277 • 2018 ACR/ARHP Annual Meeting
Outcomes of Telemedicine for Rheumatoid Arthritis in the Alaska Native Population
Elizabeth Ferucci¹, Tammy Choromanski¹, Gretchen Day² and Sarah Freeman³, ¹Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ²Clinical and Research Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ³Telehealth, Alaska Native Tribal Health Consortium, Anchorage, AK
Background/Purpose: In rheumatoid arthritis (RA), access to a rheumatologist is associated with improved quality of care and outcomes. Telemedicine has been proposed as a solution…
Abstract Number: 278 • 2018 ACR/ARHP Annual Meeting
The Effect of Patient, Prescriber and Region on the Initiation of First Biologic for Rheumatoid Arthritis: A Longitudinal Population Study
Mark Tatangelo¹, George A. Tomlinson², Michael Paterson³, Nick Bansback⁴, Tara Gomes¹, Alex Kopp³, Vandana Ahluwalia⁵ and Claire Bombardier⁶, ¹University of Toronto, Toronto, ON, Canada, ²Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴St Paul's Hospital, Centre for Health Evaluation and Outcomes Sciences, Vancouver, BC, Canada, ⁵Ontario Rheumatology Association, Brampton, ON, Canada, ⁶Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Prescribing the first biologic for rheumatoid arthritis is an important decision for physicians, payers, and patients with costs and clinical implications. Our aim was…
Abstract Number: 279 • 2018 ACR/ARHP Annual Meeting
Variations and Disparities in Healthcare Teams Among Individuals with Lupus
R. Paola Daly, Roushanac Partovi and Patricia Davidson, Lupus Foundation of America, Washington, DC
Background/Purpose: Given the systemic and complex nature of lupus, individuals with lupus are often cared for by a multi-disciplinary team, each provider playing a unique…
Abstract Number: 280 • 2018 ACR/ARHP Annual Meeting
Be Fierce. Take Control.TM an Evidence-Based Digital Lupus Awareness and Education Campaign for Young Minority Women at Risk for Lupus
R. Paola Daly¹, Nicole Wanty², Maggie Maloney¹, Stacey Boyd³, Karin Tse¹ and Karen Goldstein⁴, ¹Lupus Foundation of America, Washington, DC, ²KDH Research & Communication, Atlanta, GA, ³American College of Rheumatology, Atlanta, GA, ⁴Ogilvy, Washington, DC
Background/Purpose: Lupus is a complex, chronic autoimmune disease that has significantly higher prevalence and incidence among minority women.[i] In an effort to reduce the time…
Abstract Number: 281 • 2018 ACR/ARHP Annual Meeting
Development of an African American Lupus Community-Based Patient and Provider Education Program: Lupus Conversations
Karen Mancera-Cuevas¹, Courtnie Phillip², Cianna Leatherwood³, Chase Correia⁴, James Brucker⁴, Elmer Freeman⁵, Gail Granville⁶, Kay Mimms⁷, Patricia Canessa⁸, Candace H. Feldman³ and Rosalind Ramsey-Goldman⁹, ¹Rheumatology, Northwestern University, Chicago, IL, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Northwestern University, Chicago, IL, ⁵Northeastern University, Boston, MA, ⁶Women of Courage, Inc., Boston, MA, ⁷Lupus Society of Illinois, Chicago, IL, ⁸Illinois Public Health Association, Springfield, IL, ⁹FSM, Northwestern University, Chicago, IL
Background/Purpose: African Americans (AA) with lupus experience severe manifestations and outcomes, and a long journey to diagnosis and care. We developed and tested evidence-based, culturally…
Abstract Number: 282 • 2018 ACR/ARHP Annual Meeting
The Utility of Positive ANA Referrals at the University of Chicago
Veena Patel¹ and Anisha Dua², ¹University of Chicago, Chicago, IL, ²Section of rheumatology, University of Chicago, chicago, IL
Background/Purpose: The ANA test is nonspecific and can be difficult to interpret without understanding the limitations of the test. Referrals to Rheumatology for positive ANA…
Abstract Number: 283 • 2018 ACR/ARHP Annual Meeting
Benefits Accrued through the Implementation of Telerheumatology Services
Alexander Peck¹, Anita Pender² and C. Kent Kwoh³, ¹Division of Internal Medicine, University of Arizona College of Medicine, Tucson, AZ, ²Division of Rheumatology, Southern Arizona VA Health Care System, Tucson, AZ, ³Medicine, Division of Rheumatology, University of Arizona School of Medicine, University of Arizona Arthritis Center, Tucson, AZ
Background/Purpose: Telerheumatology services were developed at the Southern Arizona VA Health Care System (SAVAHCS) to provide specialty care to remote Community Based Outpatient Clinics (CBOCs).…
Abstract Number: 284 • 2018 ACR/ARHP Annual Meeting
Challenges and Barriers to Employment That Persons with Osteoarthritis Face at Work Due to Their Condition
Anne-Christine Rat^1,2, Alison Stewart³, Pam Rogers⁴, Dianne P. Mosher⁵ and Diane Lacaille⁶, ¹Rheumatology Department, CHRU Nancy, Vandoeuvre-lès-Nancy, France, ²Université de Lorraine, EA4360, APEMAC, Nancy, France, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ⁵Med, University of Calgary, Calgary, AB, Canada, ⁶Arthritis Research Canada/University of British Columbia, Medicine/Rheumatology, Richmond, BC, Canada
Background/Purpose: To understand the challenges that people with osteoarthritis (OA) experience at work due to their condition, for the purpose of adapting to OA the…
Abstract Number: 285 • 2018 ACR/ARHP Annual Meeting
Inflammatory Bowel Disease Is Associated with a Substantial Economic Burden in Patients with Psoriatic Arthritis and in Patients with Ankylosing Spondylitis
Martin J. Bergman¹, Patrick Zueger², Jinlin Song³, Irina Pivneva⁴, Keith A. Betts³ and Avani D. Joshi⁵, ¹Drexel University College of Medicine, Philadelphia, PA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Los Angeles, CA, ⁴Analysis Group, Inc., Montreal, QC, Canada, ⁵AbbVie, Inc., North Chicago, IL
Background/Purpose: Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) belong to a group of inflammatory arthritides known to share similar extra-articular manifestations, such as inflammatory bowel…
Abstract Number: 286 • 2018 ACR/ARHP Annual Meeting
The Prevalence and Treatment Patterns of Women of Childbearing Age with Rheumatic Diseases
Edward Lee¹, Robert Suruki², Brian Carpenter³, Ty Harkness³, Daniel Luk⁴ and Mohamed Yassine¹, ¹UCB Pharma, Smyrna, GA, ²UCB Pharma, Raleigh, NC, ³Charles River Associates, New York, NY, ⁴Charles River Associates, Boston, MA
Background/Purpose: Emerging data on exposure of infants to therapeutics through placental transfer and breastmilk could impact the management of women of childbearing age (WoCBA) with…
Abstract Number: 287 • 2018 ACR/ARHP Annual Meeting
Comparison of Real-World Costs between Patients with Rheumatoid Arthritis Treated with Subcutaneously-Administered Biologics Previously Treated with Another Biologic
Jennie H. Best¹, Paul Juneau² and Amanda Kong², ¹Genentech, Inc., South San Francisco, CA, ²IBM Watson Health, Bethesda, MD
Background/Purpose: To compare real-world healthcare costs between patients with rheumatoid arthritis (RA) who were treated with subcutaneously (SC) administered biologics after previously using at least…
Abstract Number: 288 • 2018 ACR/ARHP Annual Meeting
Burden of Illness of Treating Patients with Pemphigus vulgaris
Jennie H. Best, Margaret Michalska and Ibrahim Abbass, Genentech, Inc., South San Francisco, CA
Background/Purpose: Pemphigus vulgaris (PV) is a rare autoimmune disorder that affects the skin and mucous membranes. Many patients with PV suffer from serious infections, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].